Related Experiment Video
Updated: Aug 5, 2026
Development of Compendium for Esophageal Squamous Cell Carcinoma
Published on: April 12, 2024
MARVELD3 as a Prognostic Biomarker in Esophageal Cancer and its Relationship with m6A Modification, Cuproptosis, and
Wenbo Fan1, Chunyao Huang1, Zhulin Wang2
1Department of Thoracic Surgery and Lung Transplantation, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China.
Introduction:
The present study analyzed the specific function of MARVEL domaincontaining protein 3 (MARVELD3) in esophageal cancer (EC).
Methods:
MARVELD3 expression and its association with clinicopathological features in EC samples were analyzed using data from the TCGA and GEO databases. Enrichment analysis was performed on differentially expressed genes (DEGs) in samples with high and low MARVELD3 expression. Furthermore, the relationships of MARVELD3 with immune infiltration, response to immune therapy, N6-methyladenosine (m6A) modification, cuproptosis, and ceRNA regulatory network were explored.
Results:
In EC, MARVELD3 exhibited high expression, which was significantly correlated with the T-stage and histological type. ROC curve analysis demonstrated a high prediction accuracy of MARVELD3 for tumor prognosis. Moreover, immune infiltration analysis showed a close relationship between MARVELD3 and the immune microenvironment and immune cells in EC. Additionally, MARVELD3, the m6A modification-related gene YTHDF1, and the cuproptosis-related gene CDK5RAP1 were closely correlated. Furthermore, the predicted ceRNA regulatory network THRBIT1/ hsa-miR-23a-3p/MARVELD3 and LINC00261/hsa-miR-23a-3p/MARVELD3 axes may be involved in the pathogenesis of EC and its progression.
Discussion:
This study analyzed the involvement of MARVELD3 in EC and revealed its relationship with m6A modification and cuproptosis and its relevant ceRNA regulatory network.
Conclusion:
MARVELD3 may be a potential biomarker for EC and was closely linked to immune infiltration, response to immune therapy, m6A modification, cuproptosis, and ceRNA regulatory networks in EC.
